News | August 25, 2022
Lupin to acquire brands Ondero and Ondero - Met from Boehringer Ingelheim
The cash consideration for the above acquisition will be Euro 26 million.
The cash consideration for the above acquisition will be Euro 26 million.
Phase 2 Study of MK-2060 Currently Ongoing in People with End-Stage Renal Disease Receiving Hemodialysis
The pandemic has taught us that health is not the exclusive responsibility of only the Union Health Ministry but jointly addressed by various Ministries at the centre and through state governments
Phase 1 has already been executed with the construction of temporary OPD, guest house and boundary wall and Phase 2 of the execution is being fast tracked
The summit to demonstrate revolutionary techniques and advanced medical procedures for treating CTO
Lynparza is the first and only approved PARPi targeting BRCA-mutated HER2-negative high-risk early breast cancer
Therapy recently approved in Canada under the brand name KORSUVA
The decision follows authorization from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) in May 2022.
Phase 1 dose-escalation study to be conducted at clinical sites in the U.S., the UK, Australia, and the Philippines
The decision is based on the outcome of a prespecified interim analysis of the Phase 3 AMEERA-5 trial
Subscribe To Our Newsletter & Stay Updated
